Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD). No liver injury has been observed with tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPK...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Toxicol Sci
Asıl Yazarlar: Woodhead, Jeffrey L., Brock, William J., Roth, Sharin E., Shoaf, Susan E., Brouwer, Kim L.R., Church, Rachel, Grammatopoulos, Tom N., Stiles, Linsey, Siler, Scott Q., Howell, Brett A., Mosedale, Merrie, Watkins, Paul B., Shoda, Lisl K.M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Mechanisms of Tolvaptan-Induced Liver Injury
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216653/
https://ncbi.nlm.nih.gov/pubmed/27655350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/toxsci/kfw193
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller